Remdesivir-induced symptomatic bradycardia in the treatment of COVID-19 disease
Jomel Patrick Jacinto, Milan Patel, Justin Goh, Kenneth Yamamura
Abstract
Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, no antiviral medication to date has been proven to be beneficial except for remdesivir. With remdesivir being widely utilized in the treatment of COVID-19, many studies vouch for its overall safety profile.1 We report the first case of remdesivir-induced hemodynamically significant sinus node dysfunction that was resolved following completion of remdesivir therapy. The patient received remdesivir as an initial dose of 200 mg intravenously (IV) followed by maintenance dose of 100 mg IV for 4 days.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Bradycardia2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PandemicAnesthesiaCoronavirusInternal medicineCardiologyDiseaseVirologyInfectious disease (medical specialty)Heart rateBlood pressureOutbreakCOVID-19 Clinical Research StudiesHeparin-Induced Thrombocytopenia and ThrombosisSARS-CoV-2 and COVID-19 Research